The global leap: Chinese biopharma, athletic brands dip toes in global waters
"To out-license drugs is a very handy and clever way for a win-win… but in terms of acquiring the businesses, that's going to be really tough." – Bradley Burgess Key…
Mega licensing deal lifts 3SBio profits but core sales slip
The Chinese drugmaker delivered sharply higher earnings, thanks to a bumper deal with Pfizer to develop a new cancer drug, but its older products came under pressure Key Takeaways: 3SBio’s…
RemeGen scores out-licensing triple play with AbbVie deal
The agreement marks the drug maker’s third such transaction since last year, setting records for both its largest upfront payment and highest total deal value Key Takeaways: PD-1/VEGF bispecific antibodies…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
XtalPi scores landmark deal for AI drug discovery
The biotech has partnered with U.S. firm DoveTree in a collaboration worth up to $5.99 billion, adding to a slew of major deals for Chinese research firms this year Key…
Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
China’s biopharma sector enters the New Year on a high
- Regulatory caution dims Hong Kong SPAC outlook, while Chinese tastes drive out foreign brands
- Global brands use overseas, emotional connections to navigate cutthroat China F&B market
- Chando joins growing bevy of Chinese beauty brands at IPO ball
-
Xtep races ahead on Southeast Asia running craze
1368.HK
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
